AD
ADVB.US Advanced Biomed Inc. Common Stock
- Market cap
- USD 5.47M
- P/E
- -
- P/B
- 0.30x
- ROE
- 22.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is ADVB.US undervalued?
Graham numberThe Graham number of Advanced Biomed Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Advanced Biomed Inc. Common Stock fundamental analysis
No fundamental analysis for Advanced Biomed Inc. Common Stock yet.
Advanced Biomed Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Advanced Biomed Inc. Common Stock
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. It offers A+Pre, a device that prepares blood samples for testing; the AC-1000, a device that separates cancer cells from the rest of the blood; A+SCDrop, a device that isolates individual cells; and A+CellScan, a device that stains and automatically counts cancer cells. The com…
Full company profileAdvanced Biomed Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Advanced Biomed Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | - | 128K | 511K |
| Gross Profit | -2.03K | -4.48K | -11.9K | -12.6K | -10.7K | -6.23M | -19.7M |
| Operating Income | -1.84M | -2.37M | -3.07M | -2.54M | -3.02M | -6.23M | -19.7M |
| EBITDA | -1.78M | -2.25M | -3.37M | -2.38M | -2.92M | -6.26M | -50.0M |
| Net Income | -1.84M | -4.03M | -3.73M | -2.78M | -3.26M | 6.68M | 2.78M |
| EPS | -1.70 | -3.72 | -0.19 | -0.14 | -0.16 | 5.33 | 2.22 |
| Balance Sheet | |||||||
| Total Assets | 1.01M | 6.71M | 4.60M | 4.46M | 6.51M | 13.8M | 13.8M |
| Total Liabilities | 30.1K | 3.22M | 3.29M | 2.80M | 3.03M | 1.47M | 1.47M |
| Shareholders' Equity | 976K | 3.49M | 1.31M | 1.66M | 3.48M | 12.3M | 12.3M |
| Cash & Short-term Investments | 65.9K | 4.78M | 2.62M | 2.61M | 2.90M | 386K | 386K |
| Total Debt | 7.21K | 477K | 242K | 129K | 1.27M | 33.8K | 607K |
| Cash Flow | |||||||
| Operating Cash Flow | -474K | -741K | -2.96M | -2.13M | -5.83M | -1.95M | -2.33M |
| Capital Expenditure | 25.4K | 1.31M | 213K | 74.1K | 32.0K | 5.00 | 2.00K |
| Free Cash Flow | -499K | -2.05M | -3.18M | -2.20M | -5.86M | -1.95M | -2.33M |
| Ratios | |||||||
| ROE | -188.2% | -115.4% | -285.9% | -167.3% | -93.7% | 54.4% | 22.6% |
| ROA | -182.6% | -60.0% | -81.1% | -62.4% | -50.0% | 48.6% | 20.2% |
| Net Profit Margin | - | - | - | - | - | 5,231.3% | 544.5% |
| Debt to Equity | 0.01x | 0.14x | 0.19x | 0.08x | 0.37x | 0.00x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Advanced Biomed Inc. Common Stock dividends
Advanced Biomed Inc. Common Stock has not paid dividends in the last 6 fiscal years.
Last stock split: 1:20 on Feb 20, 2026.
Who owns Advanced Biomed Inc. Common Stock
- Insiders 61.41%
- Institutions 1.55%
- Public & others 37.04%
- Shares outstanding 1.65M
- Free float 986K
Top funds holding ADVB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 22.1K | 1.34% | 0.00% | Aug 2026 |
Top institutions holding ADVB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| XTX Topco Ltd | 0.00 | 0.00% | -100.00% | Mar 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Mar 2026 |
Advanced Biomed Inc. Common Stock company profile
- Company name
- Advanced Biomed Inc. Common Stock
- Ticker
- ADVB.US
- Exchange
- USA Stocks
- Listed since
- Mar 6, 2025
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 12
- Fiscal year end
- June
- Address
- Tower 1, W MEGA, Tsuen Wan, Hong Kong
- Phone
- 852 3158 0999
- Website
- advb.ai
About Advanced Biomed Inc. Common Stock
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. It offers A+Pre, a device that prepares blood samples for testing; the AC-1000, a device that separates cancer cells from the rest of the blood; A+SCDrop, a device that isolates individual cells; and A+CellScan, a device that stains and automatically counts cancer cells. The company provides developed dye kits used to identify different types of cancer cells. It also offers FinTruth financial verification agent platform, an enterprise AI financial verification platform designed to compare and verify financial analysis and AI-generated financial content against underlying source documents and financial rules, and to produce source-traceable and auditable results. The company was founded in 2014 and is based in Tsuen Wan, Hong Kong.
Advanced Biomed Inc. Common Stock management
4- Mr. Mingze YinCFO & Director · born 1989
- Mr. Xiaomin Chen Ph.D.CEO & Chairman · born 1977
- - AlanDirector of Investor Relations
- Dr. Hung To Pau Ph.D.Secretary · born 1974